Polyphor POL7080 And The Journey to The Land of Pyocyanea (Part 2)
![](https://i0.wp.com/allphasepharma.com/dir/wp-content/uploads/2015/10/bridge-Pyocyanea-P2.jpg?resize=640%2C180&ssl=1)
Roche’s current Phase 2 program is strangely ambiguous. RG-7929 has not made it into www.clinicaltrials.gov yet, only POL7080 is listed. An uncontrolled open label study in “patients with non-CF acute exacerbation of bronchiectasis due to P. aeruginosa requiring IV treatment” Continue reading Polyphor POL7080 And The Journey to The Land of Pyocyanea (Part 2)